Last reviewed · How we verify
Cardiovascular Agents, Other
Cardiovascular Agents, Other is a Small molecule drug developed by University of Manchester. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cardiovascular Agents, Other |
|---|---|
| Sponsor | University of Manchester |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Nasopharyngitis
- Urinary tract infection
- Diarrhoea
- Arthralgia
- Bronchitis
Key clinical trials
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) (PHASE1)
- Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
- Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
- Second Line Endovascular Treatment in Acute DVT (PHASE4)
- Cannabis Vs Opioids Pain Management Objective Testing Comparisons (NA)
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease (PHASE4)
- Cocreating Action to Improve Rationality in the Health System (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cardiovascular Agents, Other CI brief — competitive landscape report
- Cardiovascular Agents, Other updates RSS · CI watch RSS
- University of Manchester portfolio CI
Frequently asked questions about Cardiovascular Agents, Other
What is Cardiovascular Agents, Other?
Who makes Cardiovascular Agents, Other?
What development phase is Cardiovascular Agents, Other in?
What are the side effects of Cardiovascular Agents, Other?
Related
- Manufacturer: University of Manchester — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing